CALCA and cutaneous mastocytosis: Between the studies on botulinum toxin and those on CGRP monoclonal antibody, the major difference in the patient’s election was presumably that refractory subgroup of CM patients only was largely excluded for the clinical trials about CGRP monoclonal antibody.